研究概要
主要组织相容性复合体(MHC)I类和II类分子分别向CD8+和CD4+T细胞呈递抗原。
中文摘要
主要组织相容性复合体(MHC)I类和II类分子分别向CD8+和CD4+T细胞呈递抗原。在此,我们揭示了MHC I类分子在调节CD4+T细胞介导免疫中一个此前未被认识的作用。在同种异体移植物抗宿主病和肿瘤模型中,我们证明靶细胞上MHC I类分子的缺失显著增加了其对CD4+T细胞细胞毒性的易感性。转录组学和功能研究表明,这是因为靶细胞对增强的铁死亡敏感性增高。在大型人类转录组和测序数据集中,提示CD4+T细胞在MHC I类分子下调的黑色素瘤和错配修复缺陷型结肠癌患者中增强免疫检查点阻断剂介导的应答方面发挥作用。这些发现修正并扩展了MHC I类分子在CD8+T细胞和NK 细胞免疫中的已知作用,并证明了其在CD4+T细胞介导的肿瘤和同种免疫中此前未被认识的作用。
展开英文摘要原文
Major histocompatibility complex (MHC) class I and class II molecules present antigens to CD8 + and CD4 + T cells respectively. Here we uncover a previously unrecognized role for MHC class I in modulating CD4 + T cell-mediated immunity. In allogeneic graft-versus-host disease and tumor models, we demonstrate that the absence of MHC class I on target cells significantly increases their susceptibility to CD4 + T cell cytotoxicity. Transcriptomic and functional studies suggest that this was because of heightened sensitivity to enhanced ferroptosis of the target cells. In large human transcriptomic and sequencing datasets, a role for CD4 + T cells in enhancing immune checkpoint blocker-mediated responses in persons with melanoma and mismatch-repair-deficient colon cancers that have downregulated MHC class I was suggested. These findings revise and expand the known role of MHC class I in CD8 + T cell and natural killer cell immunity and demonstrate a previously unrecognized role in CD4 + T cell-mediated cancer and alloimmunity.
论文信息
- 作者
- Lauder E、Gondal M、Wu MC、Yamamoto A、Maneix L、Zhao D、Sun Y、Cieslik M
- 第一作者单位
- Immunology Program, University of Michigan, Ann Arbor, MI, USA.United States
- 通讯作者单位
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. pavan.reddy@bcm.edu.United States
- 期刊
- Nature immunology2026 May